Trial Profile
TriMaster: Randomised Double-Blind Crossover Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes Who Have Suboptimal Glycaemic Control on Dual Therapy With Metformin and a Sulphonylurea
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Pioglitazone (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TriMaster; TriMaster v1
- 01 Feb 2023 Primary endpoint has been met. (On treatment HbA1c in patients with an eGFR 90 mls/min/1.73m2 compared to patients with an eGFR 90 mls/min/1.73m2.), as per Results published in the Nature Medicine
- 01 Feb 2023 Primary endpoint has been met. (On treatment HbA1c in obese patients (BMI 30kgm-2), compared to non-obese patients), as per Results published in the Nature Medicine
- 01 Feb 2023 Results published in the Nature Medicine